Glucored Tablet is a combination oral hypoglycemic agent containing Glibenclamide 2.5 mg and Metformin 400 mg, indicated for the management of type 2 diabetes mellitus. Glibenclamide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Glucored is typically prescribed when monotherapy with either agent is insufficient to maintain target blood glucose levels. It is important to administer Glucored with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea, vomiting, and diarrhea. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoglycemia. Regular monitoring of blood glucose, renal function, and hematologic parameters is recommended during therapy. Glucored should be used as part of a comprehensive diabetes management plan, including diet and lifestyle modifications, to reduce the risk of diabetes-related complications.